home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 01/11/21

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference

Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and Patient Screening Underway for Phase 1 Clinical Trial of RTX-321 in Advanced Hu...
RUBY - Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced ...

RUBY - MVIS, PGEN, SLDB and AMWL among midday movers

Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...

RUBY - Anchiano Therapeutics, Prevail Therapeutics leads healthcare gainers; Mirum Pharmaceuticals, Mesoblast among major losers

Gainers: Anchiano Therapeutics ANCN +173%, Prevail Therapeutics PRVL +84%, BioCardia (BCDA) +40%, Solid Biosciences (SLDB) +37%, OncoCyte OCX +32%.Losers: Mirum Pharmaceuticals (MIRM) -21%, Mesoblast (MESO) -18%, Rubius Therapeutics ...
RUBY - Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods

Palm Beach, FL – December 15, 2020 – While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient’s body? The simplest way is usuall...

RUBY - MESO, EAF, RC and MDWD among after-hours movers

Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers

RUBY - ALXN, SOL, SPCE and AMC among midday movers

Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
RUBY - Arvinas, Rubius Therapeutics leads healthcare gainers; Aerpio Pharmaceuticals, SELLAS Life Sciences among major losers

Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...

RUBY - Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

RUBY - Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...
Previous 10 Next 10